TScan Therapeutics Shares Rise 17% After FDA Clears IND for Cancer Treatment
07 June 2023 - 12:25AM
Dow Jones News
By Chris Wack
TScan Therapeutics shares were up 17% to $3.24 after the U.S.
Food and Drug Administration cleared its investigational new drug
application for TSC-200-A0201, a TCR-T targeting human
papillomavirus 16.
The stock hit its 52-week high of $6.03 on May, and is up 103%
year to date.
The biopharmaceutical company said TSC-200-A0201 is its third T
cell receptor cleared for clinical development.
TSC-200-A0201 targets HPV16, which is an oncogenic virus that is
responsible for 57% of cervical cancers and approximately 21% of
head and neck squamous cell carcinomas.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 06, 2023 10:10 ET (14:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From Apr 2024 to May 2024
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From May 2023 to May 2024
